Johnson & Johnson (J&J) has committed to investing more than $55 billion in the United States over the next four years, marking a 25% increase from its previous investment cycle. This ambitious move will focus on expanding manufacturing capabilities, advancing research, and enhancing technological infrastructure.

As part of this initiative, J&J plans to construct four new state-of-the-art plants, with the first facility located in Wilson, North Carolina. The plant is expected to create 5,000 construction jobs and over 500 permanent positions. This new site will specialize in the production of treatments for cancer, immune-mediated, and neurological diseases.

The investment aligns with the U.S. administration’s push to boost domestic manufacturing. The Trump administration has proposed a 25% tariff on pharmaceutical imports, hoping to encourage companies like J&J to increase their production on U.S. soil.

This commitment highlights J&J’s long-standing dedication to U.S. manufacturing. The company already operates more manufacturing facilities in the U.S. than in any other country. With this new expansion, J&J expects to generate an annual economic impact exceeding $100 billion.

The move is part of a broader trend among major companies like Eli Lilly and Apple, which are also ramping up investments to enhance their domestic manufacturing operations.